Japan's Meiji Holdings says drug unit started late-stage trial for COVID vaccine

December 13, 2022 05:47 PM AEDT | By Reuters
Follow us on Google News:
Image source: Reuters

TOKYO (Reuters) - Japan's Meiji Holdings Co said on Tuesday its drug subsidiary had started a Phase III trial of an mRNA-based vaccine for COVID-19.

Meiji Seika Pharma had started the late-stage trial among 780 subjects in Japan, with the test period running from November to April 2024, Meiji said in a statement.

The trial will test the effectiveness of the vaccine, developed by U.S.-based Arcturus Therapeutics Inc, in comparison with the mRNA shot developed by Pfizer Inc and BioNTech SE.

The trial was partially funded by Japan's health ministry, Meiji said, adding that it aimed at establishing a domestic production system for vaccines with a government subsidy.

Japan has depended largely on imported mRNA vaccines for its COVID inoculation campaign.

Daiichi Sankyo Co of Japan said last month its mRNA vaccine candidate had been successful in a trial as a booster shot. The company plans to submit it to regulators in January 2023.

(Reporting by Rocky Swift)


The above content is directly sourced from Reuters under a contractual arrangement. The content is being provided as a convenience and for informational purposes only; and does not constitute an endorsement or approval by Kalkine Media of any of the products, services, or opinions of the organization or individual. The user is apprised that Kalkine Media bears no responsibility for the accuracy, legality, or content of Reuters, any external sites, or for that of subsequent links. The user is requested to contact Reuters directly for answers to questions regarding the content. Please note that Kalkine Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

Top ASX Listed Companies

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK